Probatebeta
Target

HTR2A

5-hydroxytryptamine receptor 2A

As of the edition of 20 October 2026, HTR2A (5-hydroxytryptamine receptor 2A, UniProt P28223) has 56 drugs tested at it and 71 companies on the list, 9 on route A and 22 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P28223
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
48
Disease areas
Mental health; Nervous system; Chemically induced; Cancer; Nutrition and metabolism; Heart and blood vessels; Inherited and neonatal; Hormones
Registered trials of its drugs
2,055

Drugs at this target

StatusCount
Marketed35
Active4
Went quiet6
Stopped6
Withdrawn from market3
Status not established2
Total56
DrugStatusFurthest phaseUS protection
RisperidoneMarketedPhase 4none listed
OlanzapineMarketedPhase 4none listed
QuetiapineMarketedPhase 4none listed
AripiprazoleMarketedPhase 4none listed
PsilocybinActivePhase 3none listed
PaliperidoneMarketedPhase 4none listed
ZiprasidoneMarketedPhase 4none listed
BrexpiprazoleMarketedPhase 4Ends 2028
LurasidoneMarketedPhase 4none listed
MirtazapineMarketedPhase 4none listed
HaloperidolMarketedPhase 4none listed
ClozapineMarketedPhase 4none listed

12 of 56 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A9
Route B22
Engaged18
Undetermined22
Total on the list71
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
Merck & Co.Route B
SanofiRoute A

The other 68 companies at HTR2A

In the product

71 companies in all; 68 are not named here, and no score is.

See the 71 companies at HTR2A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at HTR2A

Other targets in mental health

Companies holding approvals at HTR2A